bioAffinity Technologies Inc

NASDAQ:BIAFUnited States

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.

Contact Information

Headquarters

22211 West Interstate-10, Suite 1206SAN ANTONIO, TX, United States 78257

Phone

210-698-5334

Fax

916-443-1908

Executives

Executive Chairman of the Board

Steven Girgenti

President, Chief Executive Officer, Founder, Director

Maria Zannes

Chief Financial Officer, Principal Accounting Officer, Vice President

Michael Dougherty

Executive Vice President, Chief Science and Medical Officer

Vivienne Rebel

Executive Vice President, General Counsel, Secretary

Timothy Zannes